Spyre Therapeutics (SYRE) Long-Term Investments (2019)

Spyre Therapeutics (SYRE) posted Long-Term Investments of $3.0 million for Q4 2019, down 57.86% on a QoQ basis from $7.1 million in Q3 2019.

Spyre Therapeutics (SYRE) Long-Term Investments (2019) Analysis & Trends

Spyre Therapeutics' Long-Term Investments history runs 1 years deep, the most recent figure standing at $3.0 million for Q4 2019.

Quarterly Long-Term Investments changed N/A year-over-year to $3.0 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $3.0 million (changed N/A YoY) and the FY2019 annual result came in at $3.0 million, changed N/A from the prior year.
Long-Term Investments was $3.0 million for Q4 2019 at Spyre Therapeutics, down from $7.1 million in the prior quarter.
Across five years, Long-Term Investments topped out at $12.8 million in Q2 2019 and bottomed at $3.0 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	65,899.61 Bn	65,899.33 Bn	-	-
2	Nanobiotix	1,933.82 Bn	1,933.76 Bn	-	505,194.89
3	Akari Therapeutics	1,022.34 Bn	1,022.34 Bn	-	-
4	BeOne Medicines	472.68 Bn	467.89 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	122.24 Bn	114.99 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	70.08 Bn	61.33 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.46 Bn	62.46 Bn	-	-
8	Argenx Se	55.93 Bn	50.75 Bn	1.41 Bn	-
9	Alnylam Pharmaceuticals	37.59 Bn	34.58 Bn	959.66 Mn	22.17 Mn
10	Spyre Therapeutics	258.39 Mn	258.39 Mn	-	-

Download Data